All Half-Lives Are Wrong, But Some Half-Lives Are Useful

By Wright J.G.   Boddy A.V.  

Clinical Pharmacokinetics, Vol. 40, Iss. 4, 2001-01 ,pp. : 237-244

Adis International

Access to resources Recommend Favorite

Pharmacokinetic Considerations in Determining the Terminal Elimination Half-Lives of Bisphosphonates

By Kenneth C. Lasseter  

Clinical Drug Investigation, Vol. 25, Iss. 2, 2005-01 ,pp. : 107-114

Adis International

Access to resources Recommend Favorite

Elimination Half-Lives of Selected Polychlorinated Dibenzodioxins and Dibenzofurans in Breast-Fed Human Infants

By Leung Hon-Wing   Kerger Brent   Paustenbach Dennis  

Journal of Toxicology and Environmental Health, Vol. 69, Iss. 6, 2006-04 ,pp. : 437-443

Taylor & Francis Ltd

Access to resources Recommend Favorite

Starting treatment of HIV-1 infection with a simple, but potent, antiretroviral regimen produces comparable virological results as those seen when starting therapy with more drugs

By  

Inpharma, Vol. 1, Iss. 1235, 2000-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite

Armodafinil and Modafinil Have Substantially Different Pharmacokinetic Profiles Despite Having the Same Terminal Half-Lives: Analysis of Data from Three Randomized, Single-Dose, Pharmacokinetic Studies

By Darwish Mona  

Clinical Drug Investigation, Vol. 29, Iss. 9, 2009-09 ,pp. : 613-623

Adis International

Access to resources Recommend Favorite